Elizabeth Alexander

2.3k total citations
47 papers, 677 citations indexed

About

Elizabeth Alexander is a scholar working on Infectious Diseases, Small Animals and Molecular Biology. According to data from OpenAlex, Elizabeth Alexander has authored 47 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Infectious Diseases, 12 papers in Small Animals and 10 papers in Molecular Biology. Recurrent topics in Elizabeth Alexander's work include Veterinary medicine and infectious diseases (12 papers), Antibiotic Resistance in Bacteria (9 papers) and Clostridium difficile and Clostridium perfringens research (9 papers). Elizabeth Alexander is often cited by papers focused on Veterinary medicine and infectious diseases (12 papers), Antibiotic Resistance in Bacteria (9 papers) and Clostridium difficile and Clostridium perfringens research (9 papers). Elizabeth Alexander collaborates with scholars based in United States, United Kingdom and Australia. Elizabeth Alexander's co-authors include Emilio L. Ghisalberti, Marcello Pennacchio, Kyu Y. Rhee, Yana Maolana Syah, Lisa Goldberg, Christian Sandrock, Gregory J. Moran, Anita Das, Susanne Paukner and Mirella Salvatore and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and PLoS ONE.

In The Last Decade

Elizabeth Alexander

46 papers receiving 650 citations

Peers

Countries citing papers authored by Elizabeth Alexander

Since Specialization

Citations

This map shows the geographic impact of Elizabeth Alexander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Alexander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Alexander more than expected).

Fields of papers citing papers by Elizabeth Alexander

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Alexander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Alexander. The network helps show where Elizabeth Alexander may publish in the future.

Co-authorship network of co-authors of Elizabeth Alexander

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Alexander. A scholar is included among the top collaborators of Elizabeth Alexander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Alexander. Elizabeth Alexander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers 2023 ·Clinical Pharmacokinetics ·(unknown), Elizabeth Alexander, (unknown), (unknown), Stephen A. Harrison, (unknown), Marjan Hezareh, Andrew M. Lippa, (unknown), (unknown), (unknown), Jennifer E. Sager, Scott Segal, (unknown), Andrew Skingsley, Robert Williams, Esther Yoon, Daren Austin	2
2	Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19 2023 ·CPT Pharmacometrics & Systems Pharmacology ·Jennifer E. Sager, (unknown), Julie Passarell, (unknown), Xiaobin Li, Melissa Aldinger, (unknown), Andrew Skingsley, Elizabeth Alexander, Wendy W. Yeh, Erik Mogalian, (unknown), Amanda Peppercorn, Adrienne E. Shapiro, (unknown)	5
3	Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19 2023 ·Journal of Patient-Reported Outcomes ·(unknown), (unknown), Carolina Reyes, (unknown), (unknown), (unknown), Melissa Aldinger, Elizabeth Alexander, (unknown), Elias Sarkis, Anil Kumar Gupta, Adrienne E. Shapiro, John H. Powers	1
4	Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial 2023 ·Open Forum Infectious Diseases ·Jaynier Moya, (unknown), Sergio Parra, Erick Stanley Petersen Juárez, (unknown), (unknown), (unknown), Rubaba Hussain, Scott Segal, (unknown), Andrew Skingsley, Gretja Schnell, (unknown), Jennifer E. Sager, Melissa Aldinger, Elizabeth Alexander, (unknown)	2
5	Co-designing models for the communication of genomic results for rare diseases: a comparative study in the Czech Republic and the United Kingdom 2022 ·Journal of Community Genetics ·Alessia Costa, (unknown), Glenn Robert, Milan Maçek, Christine Patch, Elizabeth Alexander, (unknown), (unknown), Amy Hunter, (unknown), Radka Kremlíková Pourová, (unknown), (unknown), (unknown), Alison Metcalfe	7
6	Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities 2021 ·BMC Pulmonary Medicine ·Thomas M. File, Elizabeth Alexander, Lisa Goldberg, Anita Das, Christian Sandrock, Susanne Paukner, Gregory J. Moran	17
7	Germline FFPE inherited cancer panel testing in deceased family members: implications for clinical management of unaffected relatives 2021 ·European Journal of Human Genetics ·(unknown), Elizabeth Alexander, (unknown), Naomi L. Bowers, Andrew J. Wallace, Emma R. Woodward, Fiona Lalloo, Anne Marie Quinn, Shuwen Huang, Hélene Schlecht, D. Gareth Evans	3
8	Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin 2021 ·Journal of Global Antimicrobial Resistance ·Susanne Paukner, Lisa Goldberg, Elizabeth Alexander, Anita Das, (unknown), (unknown), Gregory J. Moran, Christian Sandrock, Thomas M. File, Jorge E. Vidal, Ken B. Waites, Steven P Gelone, Jennifer Schranz	10
9	Oral 5-Day Lefamulin for Outpatient Management of Community-Acquired Bacterial Pneumonia: Post-hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Trial 2021 ·Journal of Emergency Medicine ·Frank LoVecchio, Jennifer Schranz, Elizabeth Alexander, (unknown), Andrew Meads, Christian Sandrock, Gregory J. Moran, Philip Giordano	3
10	Constitutional de novo deletion CNV encompassing REST predisposes to diffuse hyperplastic perilobar nephroblastomatosis (HPLN) 2020 ·Journal of Medical Genetics ·(unknown), (unknown), (unknown), (unknown), Elizabeth Alexander, Elke M. van Veen, (unknown), (unknown), (unknown), D. Gareth Evans, Eamonn R. Maher, Emma R. Woodward	4
11	Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam 2018 ·Antimicrobial Agents and Chemotherapy ·Fekade B. Sime, Saurabh Pandey, (unknown), Suzanne L. Parker, Elizabeth Alexander, Jeffery S. Loutit, Stephanie Durso, David C. Griffith, Jeffrey Lipman, Steven C. Wallis, Jason A. Roberts	27
12	Effects of fluconazole on the metabolomic profile ofCandida albicans 2015 ·Journal of Antimicrobial Chemotherapy ·Aspasia Katragkou, Elizabeth Alexander, Hyungjin Eoh, Saki Raheem, Emmanuel Roilides, Thomas J. Walsh	17
13	Translational research in infectious disease: current paradigms and challenges ahead 2012 ·Translational research ·(unknown), Elizabeth Alexander, Mirella Salvatore	32
14	Prevalence, persistence, and microbiology of Staphylococcus aureus nasal carriage among hemodialysis outpatients at a major New York Hospital 2011 ·Diagnostic Microbiology and Infectious Disease ·Elizabeth Alexander, Daniel J. Morgan, (unknown), Scott A. Weisenberg, (unknown), Anna Kaltsas, James M. Chevalier, Jeffrey Silberzweig, Yolanda Barrón, José R. Mediavilla, Barry N. Kreiswirth, Kyu Y. Rhee	19
15	Clinical failure of vancomycin in a dialysis patient with methicillin-susceptible vancomycin-heteroresistant S. aureus 2009 ·Diagnostic Microbiology and Infectious Disease ·Dahlene N. Fusco, Elizabeth Alexander, Scott A. Weisenberg, José R. Mediavilla, Barry N. Kreiswirth, Audrey N. Schuetz, Stephen G. Jenkins, Kyu Y. Rhee	14
16	Mechanism of action of verbascoside on the isolated rat heart: increases in level of prostacyclin 1999 ·Phytotherapy Research ·Marcello Pennacchio, Yana Maolana Syah, Elizabeth Alexander, Emilio L. Ghisalberti	11
17	Technology, American Democracy and Health Care 1997 ·British Journal of Political Science ·Michael Moran, Elizabeth Alexander	11
18	The effect of verbascoside on cyclic 3′,5′-adenosine monophosphate levels in isolated rat heart 1996 ·European Journal of Pharmacology ·Marcello Pennacchio, Elizabeth Alexander, Yana Maolana Syah, Emilio L. Ghisalberti	28
19	Cardioactive compounds from Eremophila species 1996 ·Journal of Ethnopharmacology ·Marcello Pennacchio, Yana Maolana Syah, Emilio L. Ghisalberti, Elizabeth Alexander	41
20	Cardioactive effects of Eremophila alternifolia extracts 1995 ·Journal of Ethnopharmacology ·Marcello Pennacchio, Elizabeth Alexander, Emilio L. Ghisalberti, (unknown)	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact